Trimtech Therapeutics is a biotechnology company developing targeted protein degradation therapies for neurodegenerative and inflammatory diseases. Using its proprietary TRIMTAC and TRIMGLUE platforms, Trimtech harnesses the TRIM21 ubiquitin ligase to selectively degrade disease-causing protein aggregates while preserving healthy proteins. The company aims to advance treatments for conditions such as Alzheimer’s and Huntington’s by overcoming current limitations in protein degradation technologies.